These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 32988985)
61. Fibrodysplasia ossificans progressiva with minor unilateral hallux anomaly in a sporadic case from Northern Tanzania with the common ACVR1c.617G>A mutation. Saleh M; Commandeur J; Bocciardi R; Kinabo G; Hamel B Pan Afr Med J; 2015; 22():299. PubMed ID: 26966495 [TBL] [Abstract][Full Text] [Related]
62. The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification. Wang H; Kaplan FS; Pignolo RJ Biomolecules; 2024 Jan; 14(2):. PubMed ID: 38397384 [TBL] [Abstract][Full Text] [Related]
63. ACVR1 Function in Health and Disease. Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F Cells; 2019 Oct; 8(11):. PubMed ID: 31683698 [No Abstract] [Full Text] [Related]
64. Cell Senescence in Heterotopic Ossification. Pignolo RJ; Kaplan FS; Wang H Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672501 [TBL] [Abstract][Full Text] [Related]
65. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva. Luo Y; Alsamarah A; Zhang K; Hao J Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699 [TBL] [Abstract][Full Text] [Related]
66. Variable signaling activity by FOP ACVR1 mutations. Haupt J; Xu M; Shore EM Bone; 2018 Apr; 109():232-240. PubMed ID: 29097342 [TBL] [Abstract][Full Text] [Related]
70. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. Williams E; Bagarova J; Kerr G; Xia DD; Place ES; Dey D; Shen Y; Bocobo GA; Mohedas AH; Huang X; Sanderson PE; Lee A; Zheng W; Economides AN; Smith JC; Yu PB; Bullock AN JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33705358 [TBL] [Abstract][Full Text] [Related]
71. Patients with ACVR1 Kou S; De Cunto C; Baujat G; Wentworth KL; Grogan DR; Brown MA; Di Rocco M; Keen R; Al Mukaddam M; le Quan Sang KH; Masharani U; Kaplan FS; Pignolo RJ; Hsiao EC Orphanet J Rare Dis; 2020 Jul; 15(1):193. PubMed ID: 32727600 [TBL] [Abstract][Full Text] [Related]
72. Fibrodysplasia ossificans progressiva: lessons learned from a rare disease. Akyuz G; Gencer-Atalay K; Ata P Curr Opin Pediatr; 2019 Dec; 31(6):716-722. PubMed ID: 31693578 [TBL] [Abstract][Full Text] [Related]
73. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Shore EM; Xu M; Feldman GJ; Fenstermacher DA; Cho TJ; Choi IH; Connor JM; Delai P; Glaser DL; LeMerrer M; Morhart R; Rogers JG; Smith R; Triffitt JT; Urtizberea JA; Zasloff M; Brown MA; Kaplan FS Nat Genet; 2006 May; 38(5):525-7. PubMed ID: 16642017 [TBL] [Abstract][Full Text] [Related]
74. Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish. Allen RS; Tajer B; Shore EM; Mullins MC Elife; 2020 Sep; 9():. PubMed ID: 32897189 [TBL] [Abstract][Full Text] [Related]
75. Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva. Burdick LN; DelVichio AH; Hanson LR; Griffith BB; Bouchard KR; Hunter JW; Goldhamer DJ Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397414 [TBL] [Abstract][Full Text] [Related]
76. Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617G > A in the ACVR1 gene. Huang X; Roeder A; Li R; Beers J; Liu C; Zou J; Yu PB; Zheng W Stem Cell Res; 2021 Jul; 54():102424. PubMed ID: 34139597 [TBL] [Abstract][Full Text] [Related]